What Pandorum Technologies does

Pandorum Technologies is a Bengaluru-based clinical-stage biotechnology company founded in 2011 by IISc alumni Tuhin Bhowmick (CEO) and Arun Chandru (CTO) that develops programmable regenerative medicines through a proprietary platform integrating exosome therapeutics, biomaterials, 3D bioprinting, and scalable cellular engineering. The company operates a platform-plus-products model with four pipeline programs: Kuragenx (an exosome-based 'liquid cornea' therapy that received US FDA Orphan Drug Designation for ocular surface diseases including neurotrophic keratitis and Stevens-Johnson Syndrome), Bioengineered Cornea (bioprinted lenticules using proprietary cornea-specific bio-ink for sutureless implantation), Mini Liver (3D human liver organoids used as in vitro disease models), and Lung Regeneration (cell-free exosome therapy for post-COVID-19 pulmonary damage). The platform architecture spans four technology pillars — Bio-Materials with bio-engineered ECM mimics, Cellular Engineering with scalable 2D/3D MSC culture, Exosome & Nanotherapy with MSC-derived regenerative cell modulators, and Bio-Fabrication including 4D bioprinting for hierarchical tissue assembly.

The company's revenue model is pre-commercial across three prospective streams: future therapeutic product sales of Kuragenx and pipeline assets following regulatory approval, drug discovery services using 3D liver organoids sold to pharmaceutical and biotech customers for hepatotoxicity testing and MASH disease modeling, and licensing royalties from platform technology. As of FY24 the company is pre-revenue with reported losses of Rs 28.2 crore, with cumulative funding of approximately $43 million raised across grants, angel, Series A, Pre-Series B CCCPS, and a $18 million Series B in February 2026 led by Protons Corporate at a $91 million post-money valuation. Distribution and manufacturing scale-up are being established through CDMO partnerships with AGC Biologics (US/European supply) and Nucelion Therapeutics, a Bharat Biotech subsidiary (Asia-Pacific supply).

Pandorum serves four identifiable customer segments: ophthalmology hospitals and eye care clinics treating corneal blindness and ocular surface disease, pharmaceutical and biotech companies purchasing 3D liver organoids for drug discovery and DMPK studies, pulmonology practitioners addressing post-COVID-19 ARDS and pulmonary fibrosis, and hepatology specialists for liver tissue engineering and bio-artificial liver applications. The company operates R&D labs in Bangalore (Bangalore BioInnovation Centre and C-CAMP), San Carlos (MBC BioLabs Bay Area), Charleston (Medical University of South Carolina), and Chicago (Northwestern University Feinberg School of Medicine), with stated expansion targets across the US, Japan, and the Middle East.

Name

Pandorum Technologies

Legal name

Pandorum Technologies Pvt. Ltd.

Website

https://pandorum.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Pandorum Technologies is a Bengaluru-based clinical-stage biotech developing exosome-based regenerative therapies and 3D bioprinted tissues, with lead program Kuragenx (FDA Orphan Drug Designation for ocular surface diseases), serving ophthalmology, pharmaceutical drug discovery, pulmonology, and hepatology markets.

Ownership category

akta.pro rank

Product category

Regenerative Medicine & Tissue Engineering

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

akta.pro secondary industries

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Tissue engineering therapeutics
• Regenerative medicine platform
• Exosome-based therapies
• 3D bioprinting tissues
• Biomaterials research

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Therapeutic Product Sales: Pre-revenue company developing exosome-based therapies for tissue regeneration. Revenue expected from commercialization of Kuragenx (liquid cornea) and other pipeline products upon regulatory approval.
2. Drug Discovery Services: Mini Liver 3D organoids sold to pharmaceutical and biotech companies for drug metabolism, hepatotoxicity testing, and disease modeling applications.
3. Licensing Royalties: Platform technology may be licensed to larger pharmaceutical partners for specific therapeutic applications or research use.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Pandorum Technologies develops programmable regenerative medicine therapies through a proprietary platform combining exosome therapeutics, 3D bioprinting, biomaterials, and cellular engineering. Its core product pipeline includes Kuragenx (an exosome-based liquid cornea therapy), bioengineered corneal tissue products, Mini Liver (3D human liver organoids for drug discovery and disease modeling), and Lung Regeneration (cell-free exosome therapy for post-COVID pulmonary fibrosis). The company also offers drug discovery services using its 3D liver organoid models to pharmaceutical and biotechnology clients.

Product overview

Pandorum Technologies is a tissue engineering and regenerative medicine company developing programmable exosome-based therapies through a tunable regenerative platform. The company operates a platform-plus-products model with three core therapeutic pipelines: Kuragenx/Liquid Cornea (bioengineered cornea for vision restoration), Mini Liver (3D liver organoids for drug discovery), and Lung Regeneration (exosome therapy for pulmonary repair). The platform technology combines bio-materials, cellular engineering, exosome & nanotherapy, and bio-fabrication capabilities. The company focuses on disease-modifying, tunable exosome-based therapies targeting tissue health, inflammation, and fibrosis, with expansion beyond ophthalmology to systemic inflammatory and degenerative diseases affecting the lung, liver, and nervous systems.

Differentiator

Problem solved

Functional benefit

Brands

• Kuragenx: Flagship 'liquid cornea' therapy - exosome-based therapeutic for corneal regeneration, treating ocular surface diseases including neurotrophic keratitis and Stevens-Johnson syndrome
• Bioengineered Cornea
• Mini Liver
• Lung Regeneration

Products and services

• Kuragenx (Liquid Cornea) Kuragenx is a bioengineered exosome-based liquid cornea therapy combining specialized exosomes with biopolymeric solution. Applied as eye drops, it solidifies within minutes using visible light and promotes cornea regeneration to restore vision in patients with corneal opacity, ulcers, and neurotrophic keratitis. Targeted at hospitals and eye care clinics treating ocular surface diseases.
• Bioengineered Cornea Bioengineered corneal tissue products including bioprinted lenticules using proprietary bioinks that mimic native cornea tissue. Designed for sutureless implantation to treat corneal blindness and reduce dependency on donor corneas. Targeted at ophthalmology hospitals and eye care clinics.
• Mini Liver (3D Human Liver Organoids) 3D human liver tissue models (organoids) used for drug discovery, hepatotoxicity testing, DMPK studies, and disease modeling including NASH/MASH, steatosis, and fibrosis. Mimics in vivo disease physiology for accurate drug effect prediction. Sold to pharmaceutical and biotechnology companies for preclinical research and therapeutic development applications.
• Lung Regeneration (Exosome Therapy) Cell-free exosome-based therapy for post-COVID-19 lung trauma and pulmonary fibrosis. Uses immunomodulatory and anti-fibrotic exosomal factors to repair lung tissue damage from inflammation and fibrosis. Targeted at hospitals and pulmonology clinics treating post-viral lung damage and inflammatory lung conditions.

Quantifiable outcome

• Kuragenx can reverse ulcerative cornea to healthy state in less than a year
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• AGC BiologicscoreTechnology or IntegrationCDMO partnership with AGC Biologics in Italy for manufacturing and supply of exosome-based therapies in US and European markets. Supports global manufacturing scale-up for Kuragenx and other pipeline products.
• Nucelion Therapeutics (Bharat Biotech)coreTechnology or IntegrationPartnership with Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech, for end-to-end manufacturing including process scale-up, GMP-compliant production, and quality control of pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells. Covers Asia-Pacific distribution.
• Northwestern UniversitycoreStrategic or Co-development PartnerEstablished research and operational hub within Northwestern University facilities. Clinical partner for First in Human clinical study for Kuragenx (Liquid Cornea). Uses advanced label-free live cell imaging technologies (Holomonitor, NanoLive) for exosome characterization. Expertise in corneal stromal stem cells and ex vivo analyses.
• Medical University of South Carolina (MUSC)coreStrategic or Co-development PartnerCollaboration with MUSC Translational Research and Immunobiology Institute (TRII) for accelerated clinical translation in US. SAMPSON 1 study for COVID-19 induced ARDS using UCMSC therapy. Dr. Satish Nadig serves as Chief Medical Advisor. MUSC provides FDA registered cGMP facility for cell therapy.
• Dr. Shroff's Charity Eye HospitalcoreStrategic or Co-development PartnerClinical collaboration for corneal translational research in India. Dr. Virender Sangwan guides the corneal project. Key site for Kuragenx clinical trials in India.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• InSphero: Swiss 3D organoid and organ-on-chip company offering liver, pancreatic, and tumor models for pharma drug discovery. Closely comparable service-line peer to Pandorum Mini Liver's pharma offering.
• Emulate Inc. Commercial-stage organ-on-chip and in vitro liver models for drug discovery. Comparable to Pandorum's Mini Liver organoid drug discovery service business; both target pharma DMPK and hepatotoxicity testing.
• Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for stroke, ARDS, and inflammatory conditions. Comparable to Pandorum on cell-based therapy for pulmonary/post-inflammatory regeneration (ARDS/pulmonary fibrosis indication overlap).
• Aspect Biosystems: Canadian 3D bioprinting company developing tissue therapeutics (with partners including Novo Nordisk). Comparable to Pandorum on bioprinted tissue therapeutics platform, though focused on metabolic disease and pancreatic tissue.

Direct peers

• Capricor Therapeutics: Clinical-stage biotech developing exosome-based therapeutics (CAP-1002, CAP-2003) for cardiac and inflammatory indications. Most directly comparable to Pandorum in using MSC-derived extracellular vesicles/exosomes as a regenerative modality, with clinical-stage assets.
• Mesoblast: Commercial/clinical-stage cell therapy company using mesenchymal lineage cells for inflammatory and cardiovascular diseases. Comparable to Pandorum in MSC-derived regenerative platform with multiple clinical assets and global ambitions.
• Cellink (BICO Group): Global leader in bioprinting technology, bioinks, and lab automation for life sciences. Directly comparable to Pandorum on the 4D bioprinting and bio-ink technology platform; CellInk is already a Pandorum technology partner.
• Organovo: Pioneer in 3D bioprinting of human tissues for therapeutic and research applications, including liver tissue. Direct peer on the 3D-printed functional tissue technology axis, particularly comparable to Pandorum's Mini Liver program.
• Celularity Inc. Clinical-stage cell therapy and regenerative medicine company using placental-derived cells and exosomes. Comparable to Pandorum on MSC/exosome-based regenerative therapeutics and the goal of cell-free exosome products.

Broad incumbents

• Organogenesis Holdings: Commercial-stage regenerative medicine company selling bioengineered skin and wound healing products (Apligraf, Dermagraft). A relevant incumbent peer for Pandorum's bioengineered cornea and tissue regeneration ambitions, illustrating the commercial pathway and reimbursement challenges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pandorumtechnologies

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pandorum Technologies